Search
Selected Filter
Filter Results
Displaying 201–210 of 310 research results
-
Nov 15, 2017
ProQR Doses First Participant in Its LCA10 Therapy Clinical Trial
The company plans to report interim, six-month study results in 2018 and 12-month results in 2019.
-
Oct 13, 2017
An advisory committee comprised of FDA-selected experts voted unanimously – 16 to 0 – to recommend approval.
-
Sep 27, 2017
The Foundation's Investments Are Filling the Pipeline for Vision-Saving Therapies
In addition to funding promising biotech start-ups, the Foundation Fighting Blindness has played a critical role in developing research talent.
-
Aug 30, 2017
MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial
The MeiraGTx gene therapy involves injection of healthy copies of RPGR underneath the retina. The RPGR copies are contained in a human-engineered virus — known as an adeno-associated virus or AAV — designed to readily penetrate retinal cells to deliver the therapeutic genetic cargo.
-
Jul 26, 2017
Scientists Receive $25 Million to Develop a Vision-Restoring System that Connects to the Brain
The high-tech, vision-restoring system interfaces with the visual cortex, the back of the brain where visual input is processed to create the images we see.
-
Jul 25, 2017
The partnership will help companies and researchers quickly obtain and implement high-quality vectors for their retinal gene-therapy development efforts.
-
Jul 24, 2017
FFB-Funded Scientists Report on Nine Promising Translational Research Efforts
The Foundation Fighting Blindness has taken the translational challenge head on by investing more than $75 million in therapy-development projects with strong clinical-trial potential through its Translational Research Acceleration Program (TRAP), which includes Gund-Harrington Scholar Awards.
-
Jul 19, 2017
Twelve People Receive XLRS Gene Therapy in AGTC's Clinical Trial
AGTC’s gene therapy uses a human-engineered virus — and adeno-associated virus or AAV — to deliver normal copies of retinoschisin to the patient’s retina.
-
Jul 12, 2017
SparingVision Formed to Advance Sight-Saving Protein for RP
SparingVision received a €300,000 award known as the Honor Prize from the French Ministry of Research. The award is given to new, innovative companies in France competing in a national contest.
-
Jun 29, 2017
Researchers Find Mutation as Frequent Cause of RP in American Hispanics
The discovery can help genetic experts diagnose more patients with adRP, and it gives researchers a target for developing potential therapies.